Serum soluble ST2 is a promising prognostic biomarker in HBV-related acute-on-chronic liver failure

Serum sST2 may act as a promising biomarker to assess severity and predict prognosis of patients with HBV-ACLF and help for the early identification and optimal treatment of HBV-ACLF patients at high risk of mortality.